NCT05658458 - A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction) | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

September 19, 2024

Study Completion Date

September 19, 2024

Conditions

Chronic Heart Failure With Reduced Ejection FractionWorsening Heart Failure

Interventions

DRUG

Vericiguat (Verquvo, BAY1021189)

The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.

Trial Locations (12)

110017

Max Super Speciality Hospital, Saket, New Delhi

110029

Safdarjung Hospital, New Delhi

141002

Deep Hospital, Ludhiana

380015

Sanjivani Super Speciality Hospital, Ahmedabad

390022

Rhythm Heart Institute, Vadodara

400053

Kokilaben Dhirubhai Ambani Hospital & Medical Research Insti, Mumbai

422005

Vijan Cardiac & Critical Care Centre, Nashik

600081

Apollo Hospital Tondiarpet, Chennai

682017

Lisie Hospital, Kochi

700054

Apollo Gleneagles Hospital Limited, Kolkata

751019

All India Institute of Medical Sciences, Bhubaneswar

500 003

Krishna Institute Of Medical Science, Secunderabad